TCT 2014:美国稳定冠脉CTO PCI治疗较少

2014-09-23 傅向华 魏立业 医学论坛网

 TCT2014公布的一项研究表明,目前在美国稳定的冠状动脉疾病行慢性完全闭塞病变(CTO)经皮冠脉介入治疗(PCI)的治疗很少,与非CTO PCI相比较,它具有较低的成功率和更高的并发症发生率。CTO PCI手术的成功是与一些病人因素和术者操作经验相关的。 CTO PCI可以带来显著的临床益处,然而在非选择的病人群体中它的成功率及安全性信息是有限的,该研究试图描述目前在美国的

 TCT2014公布的一项研究表明,目前在美国稳定的冠状动脉疾病行慢性完全闭塞病变(CTO)经皮冠脉介入治疗(PCI)的治疗很少,与非CTO PCI相比较,它具有较低的成功率和更高的并发症发生率。CTO PCI手术的成功是与一些病人因素和术者操作经验相关的。

CTO PCI可以带来显著的临床益处,然而在非选择的病人群体中它的成功率及安全性信息是有限的,该研究试图描述目前在美国的CTO PCI治疗的频率、预测因素及结果情况。

研究者们入选了2009年7月1日至2013年3月31日之间的NCDR(National Cardiovascular Data Registry,美国国家心血管数据注册)CathPCI 注册研究,我们分析CTO PCI的频率与结果,并与选择性的非CTO PCI病人进行比较,并比较CTO PCI治疗的成功与失败率。使用Logistic回归方程模型来评估与手术成功和并发症的独立相关因素。

结果显示,在研究期间,CTO PCI占稳定冠状动脉疾病PCI总额的3.8% (22365/594510)。总的来说,接受CTO PCI的患者需要更高的对比剂剂量和透视时间,和更低的手术成功率(59% vs. 96%,P< 0.001),而MACE率比非CTO患者更高(1.6% vs. 0.8%,P<0.001)。在多变量分析中,几个参数(包括高龄、目前吸烟、既往心梗,搭桥病史,外周动脉疾病史,心脏骤停史,右冠状动脉CTO及术者缺乏操作经验)与CTO PCI手术可能的成功率较低是相关的。然而,术者每年操作CTO PCI的量与手术的成功是相关的,而且主要并发症并无显著增加。

原文标题:慢性完全闭塞病变经皮冠脉介入治疗的研究结果:来自NCDR(美国国家心血管数据注册)的报告


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030083, encodeId=23582030083d5, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Jul 16 18:48:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862744, encodeId=b4fb1862e443a, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sun Oct 05 20:48:00 CST 2014, time=2014-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394618, encodeId=41fb1394618af, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630049, encodeId=13f21630049fb, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030083, encodeId=23582030083d5, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Jul 16 18:48:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862744, encodeId=b4fb1862e443a, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sun Oct 05 20:48:00 CST 2014, time=2014-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394618, encodeId=41fb1394618af, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630049, encodeId=13f21630049fb, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=)]
    2014-10-05 gao_jian4217
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030083, encodeId=23582030083d5, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Jul 16 18:48:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862744, encodeId=b4fb1862e443a, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sun Oct 05 20:48:00 CST 2014, time=2014-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394618, encodeId=41fb1394618af, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630049, encodeId=13f21630049fb, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030083, encodeId=23582030083d5, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Jul 16 18:48:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862744, encodeId=b4fb1862e443a, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Sun Oct 05 20:48:00 CST 2014, time=2014-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394618, encodeId=41fb1394618af, content=<a href='/topic/show?id=d85b1e2171d' target=_blank style='color:#2F92EE;'>#TCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17217, encryptionId=d85b1e2171d, topicName=TCT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630049, encodeId=13f21630049fb, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Thu Sep 25 00:48:00 CST 2014, time=2014-09-25, status=1, ipAttribution=)]
    2014-09-25 许安

相关资讯

CIT 2014:冠脉分叉病变RESOLVE评分

研究背景冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策略对术后即刻

JAMA:冠状动脉疾病患者局部心肌变薄与疤痕负荷有关

心血管CMR分析 局部左心室壁变薄被认为是透壁性心肌梗塞和瘢痕组织的表现。然而,最近的病例报道使用延迟增强心血管磁共振(CMR)成像技术揭示了室壁变薄可能存在于有限瘢痕负荷或无瘢痕负荷患者的可能性。 为了评估局部心肌壁变薄患者并明确瘢痕负荷和机能改善之间的关系,杜克大学心血管研究中心的Raymond J. Kim博士及其同事进行了深入研究,他们发现,CMR检查显示局部室壁变薄的CAD患者中

ESC 2013:稳定性冠状动脉疾病指南

2013年9月1日,由Gilles Montalescot及UdoSechtem领导的工作小组在欧洲心脏病学会年会(ESC2013)上公布了最新的稳定性冠状动脉疾病指南。【全文阅读】本次更新的主要内容为:1.自2006年稳定性心绞痛管理与治疗指南出台之后,稳定性冠状动脉疾病(SCAD)的概念已经发生了变革,其范围更加广泛,除以冠状动脉血栓形成为主要临床表现的急性冠脉综合征外,很多CAD均属于SCA

冠状动脉杂交技术(HCR)在冠状动脉血运重建中的应用争鸣

    随着愈来愈多合并多重高危因素的冠心病病人转诊至心脏外科,心脏外科医生面临着冠心病的手术风险愈来愈高。为了减少手术创伤,降低手术风险,冠状动脉搭桥技术不断改进,包括非体外循环下不停跳冠状动脉搭桥术(OPCAB)和微创小切口冠状动脉搭桥术(MIDCAB)。MIDCAB主要适用于心脏前壁的血管,尤其是左前降支(LAD),临床中远期疗效满意。虽然经皮冠状动脉介入治疗(